Aerie Pharmaceuticals Inc (AERI, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is engaged in the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie Pharmaceuticals Inc has a market cap of $1 billion; its shares were traded at around $21.59 with and P/S ratio of 16.39. GuruFocus has detected 5 severe warning signs with Aerie Pharmaceuticals Inc. .
For the last quarter Aerie Pharmaceuticals Inc reported a revenue of $24.7 million, compared with the revenue of $14.46 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $69.9 million, For the complete 30-year financial data, please go here.. For the last five years Aerie Pharmaceuticals Inc had an average revenue decline of 0% a year.
The reported loss per diluted share was $4.39 for the year, compared with the loss per share of $2.88 in the previous year. The Aerie Pharmaceuticals Inc had an operating margin of -268.27%, compared with the operating margin of -867.38% a year before. The 10-year historical median operating margin of Aerie Pharmaceuticals Inc is -867.38%. The profitability rank of the company is 1 (out of 10).
At the end of the fiscal year, Aerie Pharmaceuticals Inc has the cash and cash equivalents of $143.9 million, compared with $202.8 million in the previous year. The long term debt was $200.8 million. Aerie Pharmaceuticals Inc has a financial strength rank of 3 (out of 10).
At the current stock price of $21.59, Aerie Pharmaceuticals Inc is traded at 69.9% discount to its historical median P/S valuation band of $71.80. The P/S ratio of the stock is 16.39, while the historical median P/S ratio is 54.52. The stock lost 44.21% during the past 12 months.
For the complete 20-year historical financial data of AERI, click here.
